B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $7 from $9 and keeps a Buy rating on the shares. The Q3 earnings update included a development plan revision for the registration-enabling Phase III VERSATILE-003 trial in HPV16-positive head and neck squamous cell carcinoma, with a sample size reduction from about 440 to roughly 350 patients while maintaining statistical power on the overall survival primary efficacy endpoint, the analyst tells investors in a research note. Management also acknowledged the potential impact of recent FDA approval of Keytruda in adjuvant and neoadjuvant HNSCC to be factored in this development plan revision, including via a recently commissioned survey of more than 50 oncologists treating HNSCC patients, the firm adds.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PDSB:
- PDS Biotechnology Highlights Clinical Progress and Q3 Results
- PDS Biotechnology price target lowered to $4.50 from $7 at Alliance Global Partners
- PDS Biotechnology reports Q3 EPS (29c), consensus (28c)
- PDSB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- PDS Biotechnology presents rationale, design for study evaluating PDS01ADC
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
